Bulum tomislav (41 résultats)

Hardback or Cased Book. Etat : New. Recent Advances in Hypertension, Hypercholesterolemia and Type 2 Diabetes. Book.

Hardback. Etat : New.

Etat : New.

Etat : New.

Etat : New.

Etat : New.

Etat : New.

Hardback. Etat : New.

HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Hardcover. Etat : new. Hardcover. Diabetes is one of the most challenging health problems in the 21st century, projected to affect 700 million people by 2045. In the last 15 years, the number of people diagnosed with type 1 diabetes increased by 45%, and those diagnosed with type 2 diabetes increased by 95%. The most devastating effects of diabetes are its chronic complications, which confer a high risk of morbidity and mortality and an increased health system cost burden. Although there is increased awareness and new therapeutic options in the treatment of diabetes, it is still the leading cause of blindness in working-age adults, the leading cause of kidney failure and dialysis, and the leading cause of nontraumatic lower-limb amputations. Although recent trends indicate a decline in certain diabetes-related complications, such as all-cause and cardiovascular mortality, individuals with diabetes continue to face a significantly elevated risk of these outcomes compared to those without the disease. Given this persistent disparity, further efforts are essential to reduce the burden of comorbidities and lower the risk of premature mortality in the diabetic population. In this context, this Reprint brings together the latest research and advancements in the understanding and management of diabetes-related comorbidities, novel therapeutic approaches, and emerging clinical insights. It includes twelve original research articles, one review article, and one systematic review, offering a comprehensive overview of current developments in the field. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Hardcover. Etat : new. Hardcover. Diabetes is the fastest-growing global health issue, with diabetic retinopathy (DR) being a common long-term microvascular complication in both type 1 and type 2 diabetes. Despite recent advancements in treatment, which have reduced diabetes-related visual impairment, DR remains the leading cause of preventable blindness in working-age adults.This Reprint, featuring eight research articles and six reviews, presents the latest molecular research and advances in DR and diabetic macular edema (DME). Topics include genetic susceptibility and the molecular basis of DR, the interrelationship between DR, DME, and diabetic nephropathy, multimodal imaging, functional tests for early DR detection, and improvements in DR screening through artificial intelligence.This Reprint also explores new therapeutic options for DR, including sirolimus-pretreated mesenchymal stem cells, dazotuftide, aldose reductase inhibitors, and the impact of modern antidiabetic treatments on endothelial progenitor cells, which can aid in restoring vascular function. Additionally, the potential role of natural products in DR treatment is examined. This new knowledge promises to enhance diagnosis and may form the basis for future therapeutic approaches. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

HRD. Etat : New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Etat : New. Print on Demand.

Etat : New. Print on Demand.

Etat : New. PRINT ON DEMAND.

Hardcover. Etat : new. Hardcover. Type 2 diabetes, the most prevalent form of diabetes associated with obesity, remains one of the leading global causes of mortality and disability. Type 2 diabetes is usually clustered with other risk factors associated with metabolic syndrome, such as hypertension and hypercholesterolemia. The central pathophysiological condition connecting these diseases is insulin resistance associated with visceral obesity. Insulin resistance alters systemic lipid metabolism and leads to the development of a characteristic form of dyslipidemia, with high levels of plasma triglycerides, low levels of high-density lipoprotein, and predominance of small, dense low-density lipoprotein. Hypertension is one of the most prevalent chronic conditions worldwide, affecting more than one billion adults and representing a leading risk factor for cardiovascular disease. However, many individuals with hypertension remain undiagnosed, untreated, or inadequately controlled. Strict management of blood pressure, along with optimization of serum lipid levels, body weight, and lifestyle factors such as smoking cessation, is crucial for controlling the global burden of cardiovascular disease and reducing the risk of premature mortality. Although recent trends indicate a decline in all-cause and cardiovascular mortality, the risk remains high, particularly among patients with diabetes. In this context, this Special Issue brings together the latest research and advancements contributing to the understanding and management of hypertension, hypercholesterolemia, and type 2 diabetes. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Type 2 diabetes, the most prevalent form of diabetes associated with obesity, remains one of the leading global causes of mortality and disability. Type 2 diabetes is usually clustered with other risk factors associated with metabolic syndrome, such as hypertension and hypercholesterolemia. The central pathophysiological condition connecting these diseases is insulin resistance associated with visceral obesity. Insulin resistance alters systemic lipid metabolism and leads to the development of a characteristic form of dyslipidemia, with high levels of plasma triglycerides, low levels of high-density lipoprotein, and predominance of small, dense low-density lipoprotein. Hypertension is one of the most prevalent chronic conditions worldwide, affecting more than one billion adults and representing a leading risk factor for cardiovascular disease. However, many individuals with hypertension remain undiagnosed, untreated, or inadequately controlled. Strict management of blood pressure, along with optimization of serum lipid levels, body weight, and lifestyle factors such as smoking cessation, is crucial for controlling the global burden of cardiovascular disease and reducing the risk of premature mortality. Although recent trends indicate a decline in all-cause and cardiovascular mortality, the risk remains high, particularly among patients with diabetes. In this context, this Special Issue brings together the latest research and advancements contributing to the understanding and management of hypertension, hypercholesterolemia, and type 2 diabetes.…

Hardcover. Etat : new. Hardcover. Since insulin discovery, thousands of lives have been saved, and the life expectancy of people with diabetes has been significantly extended. Since its discovery, insulin has been continuously improved through pharmacological development and optimized for therapeutic purposes, including the development of intermediate- and long-acting insulins, the ability to produce human insulin, and finally, the development of insulin analogs with improved properties using recombinant DNA technology. Although recent trends show a decline in complications among patients with type 1 diabetes-largely due to improved management practices and advancements in care technologies such as continuous glucose monitoring and modern insulin delivery systems-the risk of microvascular and macrovascular complications remains high. This Reprint offers a comprehensive overview of insulin secretion and action, the development and action of insulin analogs, and their impact on glycemic control and the chronic complications of diabetes. Advances in diabetes treatment have been vast in the 100 years since the discovery of insulin, resulting in extraordinary progress in the development of novel molecules to improve glucose control, simplify insulin regimens, and enhance quality of life. However, insulin remains the only replacement therapy for type 1 diabetes, and this new data presented here may encourage and support further research in this important field. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

Etat : New. Print on Demand.

Etat : New. Print on Demand.

Etat : New. PRINT ON DEMAND.

Hardcover. Etat : new. Hardcover. Diabetes is the fastest-growing global health issue, with diabetic retinopathy (DR) being a common long-term microvascular complication in both type 1 and type 2 diabetes. Despite recent advancements in treatment, which have reduced diabetes-related visual impairment, DR remains the leading cause of preventable blindness in working-age adults.This Reprint, featuring eight research articles and six reviews, presents the latest molecular research and advances in DR and diabetic macular edema (DME). Topics include genetic susceptibility and the molecular basis of DR, the interrelationship between DR, DME, and diabetic nephropathy, multimodal imaging, functional tests for early DR detection, and improvements in DR screening through artificial intelligence.This Reprint also explores new therapeutic options for DR, including sirolimus-pretreated mesenchymal stem cells, dazotuftide, aldose reductase inhibitors, and the impact of modern antidiabetic treatments on endothelial progenitor cells, which can aid in restoring vascular function. Additionally, the potential role of natural products in DR treatment is examined. This new knowledge promises to enhance diagnosis and may form the basis for future therapeutic approaches. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…